Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View PlansCash Conversion
2.84x
BIOCON's operating cash flow exceeded net income in FY 2025, indicating earnings are backed by actual cash generation.
Free Cash Flow
₹19.25B
BIOCON's free cash flow was ₹19.25B in FY 2025, up 51.1% from FY 2024.
Dividend Coverage
23.2x
BIOCON's free cash flow covered dividends 23.2x in FY 2025, leaving room for reinvestment or debt reduction.
CapEx Intensity
52.6%
Capital expenditure was 52.6% of operating cash flow in FY 2025 for BIOCON, a moderate level of reinvestment.
Hover the chart icon for YoY change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Net Income | 12.98B | 14.29B | |
| Cash flow Operating Activities | 29.54B | 40.61B | |
| Investments in PPE | -16.81B | -21.37B | |
| Cash flow Investing Activities | -10.05B | -2.34B | |
| Dividend Paid | -2.03B | -829.00M | |
| Cash flow Financing Activities | -23.33B | -18.54B | |
| Cash at beginning of period | 13.00B | 9.20B | |
| Cash at end of period | 9.20B | 29.24B | |
| Free Cash Flow | 12.73B | 19.25B |
Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025